Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Iron-deficiency, Iron Deficiency Anemia
Interventions: phytic acid; Dietary Supplement
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Thalassemia, Iron Overload, Hemochromatosis
Interventions: Nifedipine, Phlebotomy, Urinalysis, Echocardiogram, Electrocardiogram; Drug · Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Iron Deficiency (ID), Pregnancy
Interventions: Lactiplantibacillus plantarum 299v, Placebo Capsule(s); Dietary Supplement · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions: Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage); Drug
Lead sponsor: ApoPharma; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Pantothenate Kinase-Associated Neurodegeneration
Interventions: CoA-Z, Placebo; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 3 Months to 89 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Iron Deficiency Anemia
Interventions: Ferric Carboxymaltose (FCM), Iron Sucrose / Iron Dextran; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Malignant Solid Neoplasm
Interventions: Ferumoxytol, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Veliparib; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Baltimore, Maryland • Bethesda, Maryland • Rochester, Minnesota + 2 more

Conditions: Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions: FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate); Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Anemia
Interventions: Ferric Carboxymaltose, Standard Medical Care (SMC); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Healthy Term Infants
Interventions: Infant formula, Cow's milk infant formula; Other
Lead sponsor: Mead Johnson Nutrition; Industry
Eligibility: 12 Days to 16 Days
Enrollment: 399 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 17 more

Conditions: Neural Tube Defects, Folic Acid Deficiency, Spina Bifida, Anencephaly-Spina Bifida, B12 Deficiency Vitamin, Anemia, Iron Deficiency Anaemia Due to Dietary Causes
Interventions: Micronutrient fortified iodized salt; Dietary Supplement
Lead sponsor: Hydrocephalus and Neuroscience Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Anemia in Pregnancy, Preeclampsia
Interventions: Neevo® (a medical food), Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12); Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Sheffield, Alabama • Flowood, Mississippi • Gainesville, Texas

Conditions: Iron Deficiency Anemia, Iron-deficiency
Interventions: 95% condensed proanthocyanidins from grape seed extract; Dietary Supplement
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) - Refractory
Interventions: CliniMACS System; Device
Lead sponsor: Ginna Laport; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions: BQ-788, BQ-123, L-Arginine, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Lactated Ringer's; Drug
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Iron Deficiency Anemia, Iron Deficiency Anaemia
Interventions: Iron isomaltoside/ferric derisomaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Chula Vista, California • La Mesa, California • Northridge, California + 15 more

Conditions: Helicobacter Pylori Infection
Interventions: BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE, MATCHING PLACEBO; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Parkinson's Disease (PD), Parkinsonism, Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA)
Interventions: Not listed
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 90 Years
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Autism Spectrum Disorder, Insomnia
Interventions: Ferrous sulfate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 10 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Aurora, Colorado • Rochester, New York • Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation; Biological · Other · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 30 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Hemochromatosis
Interventions: Phlebotomy; Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Contrast-Induced Acute Kidney Injury
Interventions: CRMD-001-Deferiprone, Placebo; Drug
Lead sponsor: CorMedix Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more

Conditions: Neurodevelopmental Outcome
Interventions: iron; Dietary Supplement
Lead sponsor: University of Rochester; Other
Eligibility: Up to 32 Weeks
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 2 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 42
States / cities: Little Rock, Arkansas • Oakland, California • Orange, California + 31 more

Search by objective public record fields.

Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability

Oral Nifedipine to Treat Iron Overload

Probiotic Supplementation in Optimizing Iron and Hematological Status Among Pregnant Females

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

The Evaluation of Cow's Milk Formula - Study B

Using Iodized Salt to Improve Serum Folate, B12 and Iron Levels

A Retrospective Analysis of Neevo®/Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

Multiple Daily Condensed Tannin Supplementation and Iron Bioavailability: The Tannin Dose Response Trial

Haploid Allogeneic Transplant Using the CliniMACS System

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

Helicobacter Pylori and Body Iron in Adults

Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)

Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Treatment of Hemochromatosis

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

Iron Status and Myelination in Premature Infants

A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients